365 related articles for article (PubMed ID: 24053596)
1. Telomere maintenance as a target for drug discovery.
Sekaran V; Soares J; Jarstfer MB
J Med Chem; 2014 Feb; 57(3):521-38. PubMed ID: 24053596
[TBL] [Abstract][Full Text] [Related]
2. Telomeres and telomerase as targets for anticancer drug development.
Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
[TBL] [Abstract][Full Text] [Related]
3. Targeting telomeres and telomerase.
De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
[TBL] [Abstract][Full Text] [Related]
4. Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.
Maji B; Bhattacharya S
Chem Commun (Camb); 2014 Jun; 50(49):6422-38. PubMed ID: 24695755
[TBL] [Abstract][Full Text] [Related]
5. Novel anticancer therapeutics targeting telomerase.
Ruden M; Puri N
Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437
[TBL] [Abstract][Full Text] [Related]
6. Telomere inhibition and telomere disruption as processes for drug targeting.
Rezler EM; Bearss DJ; Hurley LH
Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
[TBL] [Abstract][Full Text] [Related]
7. Telomeres and telomerase: understanding basic structure and potential new therapeutic strategies targeting it in the treatment of cancer.
Sekhri K
J Postgrad Med; 2014; 60(3):303-8. PubMed ID: 25121374
[TBL] [Abstract][Full Text] [Related]
8. Telomere maintenance as a target for anticancer drug discovery.
Neidle S; Parkinson G
Nat Rev Drug Discov; 2002 May; 1(5):383-93. PubMed ID: 12120414
[TBL] [Abstract][Full Text] [Related]
9. Telomere maintenance mechanisms as a target for drug development.
Bearss DJ; Hurley LH; Von Hoff DD
Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
[TBL] [Abstract][Full Text] [Related]
10. Telomerase-Targeted Cancer Immunotherapy.
Mizukoshi E; Kaneko S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
12. Crossroads of telomere biology and anticancer drug discovery.
Seimiya H
Cancer Sci; 2020 Sep; 111(9):3089-3099. PubMed ID: 32579791
[TBL] [Abstract][Full Text] [Related]
13. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.
Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N
Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605
[TBL] [Abstract][Full Text] [Related]
15. Telomere and telomerase as targets for cancer therapy.
Tian X; Chen B; Liu X
Appl Biochem Biotechnol; 2010 Mar; 160(5):1460-72. PubMed ID: 19412578
[TBL] [Abstract][Full Text] [Related]
16. Recent patents on anti-telomerase cancer therapy.
Agrawal A; Dang S; Gabrani R
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):102-17. PubMed ID: 21854360
[TBL] [Abstract][Full Text] [Related]
17. Telomere-based cancer treatment: emerging targeted therapies.
Chen M; McLeskey SW
Clin J Oncol Nurs; 2010 Dec; 14(6):720-6. PubMed ID: 21112850
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of telomerase limits the growth of human cancer cells.
Hahn WC; Stewart SA; Brooks MW; York SG; Eaton E; Kurachi A; Beijersbergen RL; Knoll JH; Meyerson M; Weinberg RA
Nat Med; 1999 Oct; 5(10):1164-70. PubMed ID: 10502820
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells.
Misawa M; Tauchi T; Sashida G; Nakajima A; Abe K; Ohyashiki JH; Ohyashiki K
Int J Oncol; 2002 Nov; 21(5):1087-92. PubMed ID: 12370759
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
